Nowacka-Zawisza Maria, Krajewska Wanda Małgorzata
Katedra Cytobiochemii, Wydział Biologii i Ochrony Środowiska, Uniwersytet Łódzki.
Postepy Hig Med Dosw (Online). 2013 Nov 26;67:1090-7. doi: 10.5604/17322693.1077713.
The term triple-negative breast cancer (TNBC) defines breast tumors that do not express estrogen receptors, progesterone receptor or epidermal growth factor receptor HER2 on immunohistochemical analysis. TNBC accounts for 12-17% of all types of breast cancer. Molecular profiling indicated that triple-negative breast cancer represents a heterogeneous subgroup of breast cancer. Triple-negative breast cancer shares histological and genetic abnormalities with basal-like subtype of breast cancer; however, this overlap is incomplete. Breast cancer found in BRCA1 mutation carriers is also frequently TNBC. Triple-negative breast cancer does not benefit from hormonal therapies or treatments targeted against HER2. The results of ongoing studies as well as the results of clinical trials suggest that poly(ADP-ribose) polymerase inhibitors, EGFR, Hedgehog, Notch, Wnt/β-catenin, VEGF signaling inhibitors, and mTOR, Src, and Bcr/Abl kinase inhibitors used alone or in combination with other anticancer drugs might be effective in triple-negative breast cancer treatment. In this review, current knowledge on molecular characteristics of triple-negative breast cancer and its subtypes' treatment options is presented.
三阴性乳腺癌（TNBC）这一术语指的是在免疫组织化学分析中不表达雌激素受体、孕激素受体或表皮生长因子受体HER2的乳腺肿瘤。三阴性乳腺癌占所有类型乳腺癌的12% - 17%。分子谱分析表明，三阴性乳腺癌是乳腺癌的一个异质性亚组。三阴性乳腺癌与基底样亚型乳腺癌存在组织学和基因异常；然而，这种重叠并不完全。在携带BRCA1突变的个体中发现的乳腺癌也常常是三阴性乳腺癌。三阴性乳腺癌无法从激素疗法或针对HER2的治疗中获益。正在进行的研究结果以及临床试验结果表明，聚（ADP - 核糖）聚合酶抑制剂、表皮生长因子受体（EGFR）、刺猬因子（Hedgehog）、Notch、Wnt/β - 连环蛋白、血管内皮生长因子（VEGF）信号通路抑制剂，以及雷帕霉素靶蛋白（mTOR）、原癌基因酪氨酸蛋白激酶（Src）和Bcr/Abl激酶抑制剂单独使用或与其他抗癌药物联合使用，可能对三阴性乳腺癌治疗有效。在本综述中，介绍了关于三阴性乳腺癌分子特征及其亚型治疗选择的当前知识。
